21.03.2024 • NewsEvonikpartnershipprobiotics

Evonik and Vland Biotech Begin Joint Venture

Evonik Vland Biotech, a new joint venture between Evonik China and Shandong Vland Biotech, began operations on January 1, 2024. The venture aims to expand the market presence of their livestock probiotics in Greater China and develop new products. The official opening took place in Qingdao on March 14.

Evonik’s biotech platform is dedicated to creating biosolutions for healthier living. It innovates at the crossroads of chemistry, biotechnology, pharmacology, and data science. Skin applications, that enhance Evonik’s Care Solutions portfolio, exemplify these innovations.

“Vland and Evonik have been partnering for nearly 10 years. Through this relationship, we have created a strong foundation on which we can build”, said Johann-Caspar Gammelin, head of Evonik's Nutrition & Care division.

The joint venture is based at the Vland Biotech Park in Qingdao and uses Vland's production facilities in Huimin. Under the agreement with Vland, Evonik will also distribute the joint venture's portfolio outside the Greater China region. The joint venture complements Evonik's gut health portfolio with new components for formulated products and enables new solutions for gut health.

“Over the past decade, Vland and Evonik have been continuously broadened the scope of our cooperation and deepened our partnership,” said Arron Chen, Chairman and President of the Vland Group. “With the joint venture now fully operational, we are poised to capitalize on our expertise on the animal gut health and deliver effective and efficient products and solutions for our customers in China and worldwide.”

The joint venture is based at the Vland Biotech Park in Qingdao. © Evonik
The joint venture is based at the Vland Biotech Park in Qingdao. © Evonik

Company

Logo:

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read